The management of pain in the oncology patient

Obstetrics and Gynecology Clinics of North America

Volumn 28, Issue 4, 2001, Pages 819-846

  Hewitt, David J ^a  

^a EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLONAZEPAM; CODEINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DESIPRAMINE; FENTANYL CITRATE; GONADORELIN; HALOPERIDOL; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; INTERFERON; METHADONE; MORPHINE; MORPHINE SULFATE; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; STRONTIUM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANALGESIA; BONE PAIN; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CHRONIC PAIN; DELIRIUM; DRUG INDUCED DISEASE; HEADACHE; HEALTH CARE ACCESS; HUMAN; IATROGENIC DISEASE; MUCOSA INFLAMMATION; MYOCLONUS; NAUSEA; NOCICEPTION; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CONTROLLED ANALGESIA; PERIPHERAL NEUROPATHY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RADIATION INJURY; RESPIRATION DEPRESSION; REVIEW; SEDATION; TRANSCUTANEOUS NERVE STIMULATION;

EID: 0035202868     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70238-2     Document Type: Article

References (128)

1. Pain terms: A list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy
2. Neurosurgical approaches to cancer pain
3. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain
4. Opioid substitution to reduce adverse effects in cancer pain management
5. Treatment outcome in a multidisciplinary cancer pain clinic
6. Management of pain in elderly patients with cancer: SAGE Study Group. Systematic assessment of geriatric drug use via epidemiology
7. Peripheral and spinal mechanisms of nociception
8. Anticonvulsant alone in the relief of cancer pain
9. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
10. Treatment of cancer pain: Current status and future needs
11. Cancer-related neuropathic pain
12. Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine
13. The nature of suffering and the goals of medicine
14. Pain and its treatments
15. Current approaches to the management of cancer pain: A review
16. Opioid responsiveness of neuropathic cancer pain: Combined analysis of single-dose analgesic trials
17. Suffering in the advanced cancer patient: A definition and taxonomy
18. Nonopioid and opioid analgesic pharmacotherapy of cancer pain
19. The management of cancer pain
20. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies
21. Opioid pharmacotherapy in the management of cancer pain: A survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration
22. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain
23. Subcutaneous opioid infusions at home
24. Common symptoms in patients with advanced cancer
25. The prevalence and severity of pain in cancer
26. The pharmacological management of cancer pain. Part 1. The role of nonopioid and adjuvant drugs
27. Spinal analgesia in terminal care: Risk versus benefit
28. Ketobemidone, methadone and pethidine are noncompetitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord
29. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: A meta-analysis
30. Pain assessment and cancer pain
31. Management of cancer pain
32. World Health Organization-International Association for the Study of Pain: Joint initiatives in cancer pain relief
33. Methadone in cancer pain management: Individualize dose and titrate to effect
34. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: A dose-seeking study
35. The d- and l-isomers of methadone bind to the noncompetitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord
36. Assessment and treatment of neuropathic cancer pain following WHO guidelines
37. Assessment of cancer pain: A prospective evaluation in 2266 cancer patients referred to a pain service
38. Undertreatment of cancer pain: Barriers and remedies
39. Correlation of patient and caregiver ratings of cancer pain
40. Cancer pain emergencies: A protocol for management
41. Controlled-release oxycodone and morphine in cancer related pain
42. Neuroimaging of pain
43. Differences among raters evaluating the success of EMLA cream in alleviating procedure-related pain in children with cancer
44. Calcitonin in phantom limb pain: A double-blind study
45. Rationale for the use of bisphosphonates in breast cancer
46. Evaluating the efficacy of EMLA in alleviating pain associated with lumbar puncture: Comparison of open and double-blinded protocols in children
47. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain
48. Pain forum. Part 2. Neuropathic pain
49. Immediate response of phantom limb pain to calcitonin
50. Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients
51. A pilot study to assess the efficacy of salmon caldtonin in the relief of neuropathic pain caused by extraskeletal metastases
52. Dose ratio between morphine and methadone in patients with cancer pain: A retrospective study
53. Substitution of another opioid for morphine: Methadone can be used to manage neuropathic pain related to cancer
54. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: Clinical observations
55. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood
56. Efficacy of desipramine in painful diabetic neuropathy: A placebo-controlled trial
57. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy
58. Opioid sensitivity of chronic pain: A patient-controlled analgesia method
59. Responses in muscle afferent fibers of slow conduction velocity to contractions and ischemia in the cat
60. Neuraxial techniques for cancer pain: An opinion about unresolved therapeutic dilemmas
61. Problems of long-term spinal opioid treatment in advanced cancer patients
62. Alternatives to oral opioids for cancer pain
63. Trial of a topically administered local anesthetic (EMLA cream) for pain relief during central venous port accesses in children with cancer
64. Analgesia with epidural calcitonin in cancer patients
65. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
66. The use of analgesics in the management of pain in rheumatic diseases
67. The use of methadone in cancer pain poorly responsive to other opioids
68. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia
69. Visceral pain: A review of experimental studies
70. Treatment of cancer pain
71. Antidepressants in cancer pain
72. The use of controlled-release oxycodone for the treatment of chronic cancer pain: A randomized, double-blind study
73. Pharmacologic management of bone pain in the cancer patient
74. Factors influencing quality of life in cancer patients: The role of transdermal fentanyl in the management of pain
75. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine
76. Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
77. Managing cancer pain poorly responsive to systemic opioid therapy
78. Cancer pain management
79. Adjuvant analgesics in pain management
80. Pain management: Theory and practice
81. Controversies in the long-term management of analgesic therapy in patients with advanced cancer
82. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions
83. Breakthrough pain: Definition, prevalence and characteristics
84. Management of cancer pain
85. Breakthrough pain: Characteristics and impact in patients with cancer pain
86. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study
87. Symptom prevalence, characteristics and distress in a cancer population
88. High-dose intravenous pamidronate for metastatic bone pain
89. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer
90. Management of bowel obstruction in advanced cancer
91. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio?
92. Strontium 89 therapy for the palliation of pain due to osseous metastases
93. Procedural control of cancer pain
94. The philosophy of terminal care
95. Salmon calcitonin in cancer pain: Comparison between two different treatment schedules
96. Etidronate and calcitonin for cancer bone pain
97. Cancer pain management according to WHO analgesic guidelines
98. Salmon calcitonin in the treatment of bone metastases
99. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain
100. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management
101. The scope of the cancer pain problem
102. The World Health Organization Cancer Pain and Palliative Care Program: Past, present, and future
103. New clinical experience with tramadol
104. Pain killing with calcitonin nasal spray in patients with malignant tumors
105. Prognostic factors in the management of metastatic epidural spinal cord compression
106. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
107. Antidepressants for cancer pain and other painful syndromes with deafferentation component: Comparison of amitriptyline and trazodone
108. Field-testing of the WHO guidelines for cancer pain relief: Summary of demonstration projects
109. Quality-of-life assessment during a palliative care programme
110. Antidepressants increase bioavailability of morphine in cancer patients
111. Symptom prevalence and control during cancer patients' last days of life
112. WHO guidelines for the use of analgesics in cancer pain
113. Intraspinal morphine for cancer pain
114. Pain control and the World Health Organization analgesic ladder
115. Physician attitudes and practice in cancer pain management: A survey from the Eastern Cooperative Oncology Group
116. Calcitonin in phantom limb pain
117. Introduction
118. Controlled-release morphine tablets in patients with chronic cancer pain: A narrative review of controlled clinical trials
119. Corticosteroids as adjuvant analgesics
120. Antidepressant drugs as adjuvant analgesics
121. Sublingual absorption of selected opioid analgesics
122. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain
123. Unmet analgesic needs in cancer patients